United States: Podcast: Non-Binding Guidance: FDA's Regulation Of Products Containing CBD

Ropes & Gray's new podcast series, Non-binding Guidance, highlights FDA regulatory developments and trends affecting the life sciences industry. In this inaugural episode, Ropes & Gray lawyers Al Cacozza, Sarah Blankstein and Joshua Oyster discuss how the FDA is currently regulating products containing cannabidiol, or CBD, and what to expect from FDA and Congress in the wake of FDA Commissioner Scott Gottlieb's surprise resignation this month. The 2018 Farm Bill, signed into law last December, legalized hemp and its non-psychoactive ingredient CBD and distinguished both from marijuana, which is still considered by the federal government to be an illegal narcotic.  But the Farm Bill  left a cloud of uncertainty hanging over the emerging CBD industry because it expressly allowed FDA to continue unchanged its oversight and regulation of CBD products.  Tune in to this lively discussion of the repercussions of the Farm Bill, how the FDA and state agencies are responding, and what investors and other stakeholders should know.

Transcript:

Kellie Combs: Hello, I'm Kellie Combs, a partner in the life sciences practice group at Ropes & Gray and based in our Washington, D.C. office. Welcome to Non-binding Guidance, a new podcast series from Ropes & Gray focused on current trends in the FDA regulatory space, as well as other important developments affecting the life sciences industry. On today's inaugural episode, my colleagues will be discussing FDA regulatory issues associated with products containing cannabidiol, or "CBD," a compound found in cannabis plants. I'll turn it over now to my partner Al Cacozza to kick off the discussion.

Al Cacozza: Thank you, Kellie. And we are so pleased to be initiating this exciting new podcast series. I'm Al Cacozza, a life sciences partner based in our Washington, D.C. office. And today I'm joined by my colleagues Sarah Blankstein, who is out of our Boston office, and Josh Oyster, who is here in Washington with me. In this podcast, we're going to be discussing a topic that has garnered significant attention from consumers, researchers, investors, industry stakeholders and regulators alike in recent months—it's the marketing of products containing cannabidiol, or CBD. Specifically, we are going to focus on how the FDA is going to regulate these products in the marketplace, how they are doing it currently and how hopefully, we will give you some ideas on how they might be doing it in the future.

Before we get started on the regulatory discussion, let me provide you with a quick background on why this topic has generated so much recent interest. CBD, like THC, is a compound contained in cannabis plants. The two most famous species of cannabis plants are hemp and marijuana, but unlike THC, CBD is not known to have psychoactive effects. Now in recent years, the market for CBD-containing products has exploded—it's been found in body lotions, pain relief creams, dietary supplements and now also showing up in foods such as candies, snacks, drinks and even now pet foods. Fueling this trend has been a limited amount of evidence that CBD might treat pain, seizures, nausea, muscle spasms linked to multiple sclerosis and other conditions. Of course, there's also been a healthy dose of not only celebrity hype, but a significant amount of discussion amongst social media influencers, so it's really been a very popular topic on the internet and within social media. We are seeing lots of different uses and frankly sales in the area.

Last June, FDA approved the drug Epidiolex (the active ingredient of which is CBD) for the treatment of seizures associated with two rare forms of epilepsy based on the results of three pivotal, randomized, double-blind, placebo-controlled clinical trials. So clearly, that was a very standard prescription drug research regimen, and this is the first drug approved that contains CBD as an active ingredient. Then last December, President Trump signed the Agriculture Improvement Act of 2018 (commonly known as the Farm Bill). The Farm Bill created a regulatory framework for the federal legalization of the production of cannabis sativa (which is the hemp variation of the cannabis plant), including the "de-scheduling" of hemp and certain hemp derivatives under the Federal Controlled Substances Act ("CSA"). Prior to the 2018 Farm Bill, hemp and its derivatives had been considered Schedule 1 narcotics under the Controlled Substances Act, identical to marijuana. Now as a result of the Farm Bill, hemp has been decoupled from that and it carves out hemp and hemp derivatives (including CBD) that have a THC concentration of 0.3% or less from the definition of marijuana under the Controlled Substances Act.

Hemp legalization enjoyed wide-spread bipartisan support and has been touted by many as having the potential for creating new opportunities for investment—not only in hemp cultivation, but also in the manufacturing and distribution of hemp-derived products like CBD. In fact, there are many states, many of them previously focusing on tobacco that are now transferring a number of their agriculture crops to hemp production, including Kentucky, where Senator McConnell was one of the leading advocates for this Farm Bill. However, despite the provisions of the Farm Bill, many federal, state and local regulatory barriers remain in place and for investors and stakeholders looking to enter or expand current activities in this market, they need to understand and carefully navigate those existing regulations. Today, we are going to focus primarily on the FDA regulatory considerations for CBD and CBD products. The 2018 Farm Bill expressly, expressly carved out FDA and said the bill has no effect whatsoever on FDA's jurisdiction and existing authority over products that contain CBD or hemp. And immediately after the Farm Bill's enactment, or I think literally the day after its enactment, FDA Commissioner Scott Gottlieb issued a statement addressing the impact of the law with respect to FDA's regulation of products containing CBD and other cannabis-derived compounds. Let me turn to you now Sarah and Josh—can you walk us through and tell us what are some of the key takeaways of Commissioner Gottlieb's announcement?

Sarah Blankstein: Well, the clear message Commissioner Gottlieb had was this—the Farm Bill doesn't change anything from an FDA regulatory perspective. FDA continues to regulate CBD as it always has, with its regulations turning on how the products are classified by FDA based on the intended uses of the products and their ingredients. So CBD in a cosmetic is going to be regulated as a cosmetic, CBD in animal drugs as animal drugs, in food as food. And CBD in a drug product is regulated as a drug, so it requires an investigational new drug application (or IND) to be in place to conduct clinical studies with CBD-containing drugs and FDA will have to approve that product prior to marketing based on a showing of substantial evidence of safety and effectiveness. What's changed for CBD-drug products under the Farm Bill is really from a DEA perspective—if it's no longer a controlled substance, then the DEA requirements around registration, recordkeeping, reporting and security for clinical trials are no longer in play. And, once the drug is approved, it's no longer going to be scheduled.

Josh Oyster: Thanks Sarah. Another key takeaway from Commissioner Gottlieb's statement is the FDA's particular concern with the number of drug claims being made about products not approved by the FDA that contain CBD or other cannabis-derived compounds, and Commissioner Gottlieb indicated that this would be an FDA enforcement priority. Products that claim to treat or cure a disease or condition are by definition drugs and must be approved by FDA prior to marketing based on, as Sarah said, a showing of substantial evidence safety and effectiveness. Of course, dietary supplement products can make certain claims, but those have to be structure-function claims (such as improving digestion) and not disease claims (an example of which might be treating the symptoms of inflammatory bowel disease). Similarly, cosmetics may make certain claims to beautify and alter the appearance, but cosmetics are not permitted to make disease claims or structure-function claims. FDA's focus on CBD-containing products making drug claims is borne out by looking at FDA warning letters, of which FDA has issued many to both food and supplement and cosmetics manufacturers since 2015, each focused on impermissible drug claims.

Sarah Blankstein: And there was another point Gottlieb focused on in his statement—one that is really critical for investors in this area. And that point is around the impact of the exclusionary clause introduced into the Food, Drug and Cosmetic Act (or FDCA) by DSHEA (the Dietary Supplement Health and Education Act of 1994).

Al Cacozza: Sarah, can you tell us what investors and stakeholders really should know about that exclusionary clause?

Sarah Blankstein: Sure, thanks Al. So, many of the CBD products we see on the market right now are foods and dietary supplements—there are over 750 brands out on the market right now. But as Commissioner Gottlieb pointed out in his December statement, and as embodied in several FDA warning letters for CBD products, the agency's position is that CBD cannot be sold as a food additive or dietary supplement because of the exclusionary clause. And what the exclusionary clause does is it defines a supplement (and food additives) to not include an article if it's approved as a new drug or is authorized for investigation as a new drug for which substantial clinical investigations have been conducted IF that article (so here CBD) was not previously marketed in a dietary supplement or food. If it was not previously marketed in a supplement or food, then FDA would need to issue a regulation specifically permitting its use in a supplement or food. So the issue for CBD-containing foods and supplements is the June 2018 approval of GW Pharma's drug Epidiolex. According to FDA, substantial clinical investigations of CBD to support that approval were undertaken under an IND prior to CBD being marketed in a food or supplement. So, unless FDA issues a regulation to specifically permit the use of CBD in foods and supplements—something Commissioner Gottlieb indicated in his statement that the agency is "evaluating" currently—FDA believes that marketing foods and supplements with CBD right now is illegal and in violation on the exclusionary clause.

Al Cacozza: So Josh, given the FDA position that these products are illegal under the exclusionary clause, have we seen FDA taken any enforcement actions against CBD-containing foods and supplements?

Josh Oyster: That's a good question, Al. As I mentioned briefly, FDA has issued warning letters in this space—those letters have been focused primarily on products making disease claims, such as claims to treat cancer and Alzheimer's. And Commissioner Gottlieb reiterated in his December statement after the Farm Bill was passed that FDA's enforcement focus is really on those types of products, the ones making disease claims. But that's not to say that FDA could not start to take a more active role in enforcing against food and supplement products containing CBD, even absent disease claims on the basis of the exclusionary clause that Sarah described. And maybe now that there's a drug on the market containing CBD, Epidiolex, there's going to be more motivation on that front for FDA to keep these CBD-containing supplements off the market. There's also a role for state regulation and we have seen some states and even some cities, such as Maine, Cincinnati and New York City, relying on FDA's invocation of the exclusionary clause to say that CBD-containing foods and supplements can't be on the market in their particular location.

Al Cacozza: Sarah and Josh, we've seen a lot of CBD cosmetics products on the market. What do you think FDA's considerations are for products in this particular space that contain CBD?

Sarah Blankstein: Well, FDA hasn't directly addressed the question of whether CBD could be marketed in a true cosmetic product without any disease claims. But there's a different legal analysis at play for cosmetics than foods and dietary supplements. Most notably, there is no exclusionary clause for cosmetic ingredients, meaning that the clinical investigations of Epidiolex and FDA's approval of Epidiolex are not relevant to the legality of CBD-containing cosmetics. And there's no approval or notification required for cosmetic products and ingredients, though they must be safe for consumers under the labeled and customary conditions of use.

Josh Oyster: As mentioned, we've seen FDA issue several warning letters for CBD-containing cosmetics, such as topical lotions or creams, but those letters again focus primarily on the fact the products made disease claims and not necessarily on the fact that the products contained CBD specifically.

Sarah Blankstein: Al, where do you think we go from here? What lies ahead for the regulation of CBD products by FDA?

Al Cacozza: That is frankly the most interesting question, Sarah. In Commissioner Gottlieb's December statement as we discussed, he announced that FDA intended to hold a public hearing to gather input on products containing cannabis-derived compounds and how FDA can make the legal pathways for these products more predictable and efficient. And again, in testimony before Congress in late February, Commissioner Gottlieb stated that he intended to convene that meeting, that public meeting, sometime in April.

Now a complicating factor is that on March 5, Commissioner Gottlieb announced his resignation, which we expect to take effect in early April. HHS Secretary Azar has already announced that Dr. Ned Sharpless, the current director of the National Cancer Institute, will assume the role of Acting Commissioner of FDA upon Gottlieb's departure. And we do not know, nor have we heard a particular statement from Dr. Sharpless on his views related to CBD. Nonetheless, recently (a few days ago), Commissioner Gottlieb in what I guess would be considered maybe a valedictory interview with the Brookings Institution indicated that FDA is going to be establishing a very high-level working group to clarify the agency's position on CBD. That working group, which is expected to be announced in a few days formally, will be chaired by Dr. Amy Abernethy (who is the FDA's principal deputy commissioner for food and drugs) as well as Lowell Schiller (FDA's acting associate commissioner for policy). Commissioner Gottlieb explained that the goal of the working group will be to come up with options to consider on how to allow CBD use in food and supplement products. In fact, Commissioner Gottlieb acknowledged that the current regulatory pathway to consider CBD as part of a food or a food supplement product would take a number of years and is frankly unprecedented in FDA's regulatory scheme. So what he did acknowledge was that the fastest way to clarify the situation would be for legislative action. And he indicated that he thought that the high-level working group would be shooting for a goal of developing a package to present to Congress hopefully by the end of the summer where Congress could consider writing new legislation to give FDA authority to consider this issue under a more expedited basis. Nonetheless, the future is somewhat uncertain. Obviously the impact of Dr. Gottlieb's departure and the work of this new working group remain to be seen, both with respect to whether the FDA takes a more aggressive or flexible regularly approach to cannabis-derived products and the speed at which FDA decides to pursue either potential regulatory or more likely legislative proposals. So in the meantime, as we have been discussing, numerous states and municipalities are also going to be actively involved in this area and whether or not they take an, again, aggressive stance or follow the current FDA policy of cracking down on CBD products as has been in the case in Maine, Ohio and New York City—we will have to wait and see. Obviously, we need to monitor the situation, but I think it's fair to conclude that this is a very dynamic situation and we will have to see how the regulatory and legislative issues pan out.

Sarah and Josh I want to thank you both for joining me today and sharing your insights on this very topical discussion about CBD and FDA regulation.

Kellie Combs: Thanks for tuning in today to our new podcast Non-binding Guidance, brought to you by our FDA regulatory attorneys in the life sciences practice at Ropes & Gray. For more information about our practice, or other topics of interest to life sciences companies, please visit our FDA regulatory and life sciences practice pages at www.ropesgray.com. You can also subscribe to Non-binding Guidance and other RopesTalk podcasts in Ropes & Gray's podcast newsroom on our website, or by searching for Ropes & Gray podcasts in iTunes or Google Play. Thanks again for listening.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions